Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 29.
doi: 10.2215/CJN.0000000843. Online ahead of print.

How I Treat Challenging Cases of Antibody-Mediated Glomerular Diseases

Harish Seethapathy  1 , Ayman Al Jurdi, Orhan Efe, Anushya Jeyabalan, Gabriel Sauvage, Karen Laliberte, John L Niles
Affiliations

How I Treat Challenging Cases of Antibody-Mediated Glomerular Diseases

Harish Seethapathy et al. Clin J Am Soc Nephrol. .
No abstract available

Keywords: ANCA; glomerular disease; glomerular diseases; immunosuppression; lupus nephritis; membranous nephropathy.

PubMed Disclaimer

References

    1. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008;73(1):117–125. doi: 10.1038/sj.ki.5002628 - DOI
    1. Stone JH, Merkel PA, Spiera R, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232. doi: 10.1056/NEJMoa0909905 - DOI
    1. Rovin BH, Furie R, Latinis K, et al.; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–1226. doi: 10.1002/art.34359 - DOI
    1. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–1286. doi: 10.1136/annrheumdis-2012-202844 - DOI
    1. Zonozi R, Laliberte K, Huizenga NR, et al. Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up. Am J Kidney Dis. 2021;78(6):793–803. doi: 10.1053/j.ajkd.2021.04.014 - DOI

LinkOut - more resources